Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

NCT05726370 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer
Resectable Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Second Primary Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: Pembrolizumab
DRUG: CISPLATIN
DRUG: Carboplatin
DRUG: Docetaxel

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]